Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
The EyePoint, Inc. (EYPT) news page on Stock Titan aggregates company-reported updates and market-moving announcements for this clinical-stage biopharmaceutical business focused on serious retinal diseases. EyePoint’s disclosures emphasize its lead investigational product, DURAVYU™ (vorolanib intravitreal insert), and its progress through late-stage clinical development, making corporate news particularly relevant for investors tracking ophthalmology and retinal therapeutics.
Visitors can review news covering clinical milestones, such as enrollment completion and data safety monitoring committee recommendations for the Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration (wet AMD), as well as the design and initiation of the pivotal Phase 3 COMO and CAPRI trials in diabetic macular edema (DME). Company releases also highlight Phase 2 data from the DAVIO 2 and VERONA studies, which EyePoint cites as demonstrating meaningful and sustained improvements in vision and anatomy with favorable safety profiles.
In addition to clinical trial updates, EyePoint’s news includes financing and corporate developments, such as underwritten public offerings, at-the-market equity programs, and inducement grants under Nasdaq Listing Rule 5635(c)(4). These items provide context on how the company funds its DURAVYU programs and earlier-stage pipeline initiatives. Investors can also follow announcements about conference presentations at major healthcare and ophthalmology meetings and investor conferences, where EyePoint discusses its clinical data, trial designs, and development strategy.
By monitoring the EYPT news feed, readers can see how EyePoint communicates progress on its investigational sustained-delivery approach, interactions with regulators, and key risk disclosures referenced in forward-looking statements. This page is useful for those who want a centralized view of EyePoint’s official announcements, ranging from clinical milestones and safety updates to capital-raising activities and corporate governance events.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a leading developer of therapeutics for serious retinal diseases, has announced its upcoming participation in the 2025 RBC Capital Markets Ophthalmology Virtual Conference.
The company's President and CEO, Jay S. Duker, M.D., will engage in a fireside chat scheduled for April 4, 2025, at 10:00 a.m. ET. Investors and interested parties can access the live webcast and subsequent replay through the Investors section on EyePoint's website at www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has announced the granting of non-statutory stock options to four new employees as inducement awards. The grants, approved by the Compensation Committee on March 14, 2025, include options to purchase up to 34,500 shares of common stock at an exercise price of $6.52 per share.
The stock options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining amount vesting in equal monthly installments over the following three years. The vesting is contingent upon continued employment with EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 and full-year 2024 financial results, highlighting significant progress in its DURAVYU clinical trials. The LUGANO Phase 3 trial for wet AMD is over 50% enrolled, with both LUGANO and LUCIA trials expected to complete enrollment in H2 2025 and topline data in 2026.
The company reported positive Phase 2 VERONA trial results for DURAVYU in DME, meeting primary and secondary endpoints. Q4 2024 financial results showed total net revenue of $11.6M (down from $14.0M in Q4 2023), with a net loss of $41.4M ($0.64 per share).
Full-year 2024 results included total net revenue of $43.3M (compared to $46.0M in 2023) and a net loss of $130.9M ($2.32 per share). The company maintains a strong financial position with $371M in cash and investments as of December 31, 2024, providing runway into 2027.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a developer of innovative therapeutics for serious retinal diseases, has announced its participation in two major upcoming investor conferences in March 2025.
The company will deliver a corporate presentation at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 4:20 p.m. ET. Additionally, EyePoint will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET.
Investors can access live webcasts and archived replays of both presentations through the Investors section of EyePoint's website at www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has scheduled its fourth quarter and full-year 2024 financial results announcement for March 5, 2025. The company, which focuses on developing innovative therapeutics for serious retinal diseases, will host a conference call and webcast at 8:30 a.m. ET.
Investors and interested parties can access the live conference call through a registration link, while a live audio webcast will be available through the Investors section of EyePoint's website. A replay of the webcast will be accessible on the corporate website after the call concludes.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its President and CEO, Jay S. Duker, M.D., will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th, 2025, at 9:10 a.m. ET.
During the presentation, EyePoint will provide an enrollment update for its ongoing DURAVYU™ Phase 3 pivotal program in wet age-related macular degeneration (wet AMD). Additionally, the company will share additional subgroup analyses from the Phase 2 VERONA clinical trial of DURAVYU in diabetic macular edema (DME).
The presentation will be available via live webcast with an archived replay accessible through the Investors section of EyePoint's website at www.eyepointpharma.com. EyePoint is focused on developing and commercializing innovative therapeutics for patients with serious retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to two new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on February 14, 2025, include options to purchase up to 21,000 shares of common stock at an exercise price of $6.50 per share.
The options have a ten-year term and follow a four-year vesting schedule, with 25% vesting on the first anniversary and the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint Pharmaceuticals.
EyePoint Pharmaceuticals announced positive six-month results from its Phase 2 VERONA clinical trial of DURAVYU™ for Diabetic Macular Edema (DME). The trial met its primary endpoint with both DURAVYU doses (1.34mg and 2.7mg) showing extended time to first supplemental injection versus aflibercept control.
The DURAVYU 2.7mg dose demonstrated significant improvements, including: +7.1 letter BCVA gain, 76-micron CST reduction at week 24, and 73% supplement-free rate compared to 50% for aflibercept. The treatment showed immediate bioavailability and maintained efficacy throughout the six-month trial with no DURAVYU-related serious adverse events.
The company plans to initiate a Phase 3 non-inferiority pivotal program by the end of 2025, following FDA discussions in Q2. The VERONA trial included 27 patients and evaluated safety, visual acuity changes, and central subfield thickness as key endpoints.
EyePoint Pharmaceuticals (NASDAQ: EYPT), a company focused on developing therapeutics for serious retinal diseases, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. Jay S. Duker, M.D., the company's President and CEO, will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 9:30 a.m. ET.
Interested parties can access the webcast and subsequent replay through the Investors section of EyePoint's website at www.eyepointpharma.com.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to four new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee on January 15, 2025, allow the purchase of up to 30,300 shares of common stock at an exercise price of $7.69 per share, matching the closing price on the grant date.
The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first anniversary, with the remaining shares vesting in equal monthly installments over the following three years. Vesting is contingent upon continued employment with EyePoint.
FAQ
What is the current stock price of EyePoint (EYPT)?
What is the market cap of EyePoint (EYPT)?
